Tengjun Biotechnology Corp.

Tengjun Biotechnology Corp.

TJBH
Tengjun Biotechnology Corp.US flagOther OTC
2.00
USD
- -
- -
201.42MMarket Cap
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.87
1.07
Basic EPS, GAAP
- -
-0.01
- -
- -
- -
- -
- -
- -
- -
-0.04
-0.04
0.14
0.07
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
-0.03
-0.04
0.02
0.23
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.01
-0.02
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.13
-0.15
0.1
0.09
Tangible Book Value per Share
- -
- -
- -
- -
- -
-0.01
-0.01
-0.01
-0.01
-0.06
-0.11
0.19
0.16
Basic Weighted Avg Shares
8
4
8
36
36
37
38
38
40
19
20
80
96
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
150
103
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
-229,808.62
- -
10.7
10.92
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
-1
-1
11
7
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
21.66
27.83
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
-238,236.55
- -
7.56
6.9
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
-10
-12
7
7
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
-1
-2
15
15
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
385.98
616.45
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
Dec'22
Mar'23
Jun'23
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
96
99
101
Market Capitalization
- -
2,669
3,442

Working Capital

FRC

in mil. unless spec.
Dec'22
Mar'23
Jun'23
Total Current Assets
51
165
430
Cash, Cash Equivalents & STI
3
12
25
Accounts Receivable, Net
- -
- -
- -
Inventories
1
1
2
Total Current Liabilities
44
158
424
Payables & Accruals
44
40
38
ST Debt
- -
- -
- -
Deferred Revenue
- -
118
385

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-62.35%
-755.04%
Free Cash Flow
- -
270.34%
-253.94%
Net Income, GAAP
-23.09%
-106.26%
-1,617.92%
Sales/Revenue/Turnover
- -
- -
51,771,188.97%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
4
51
36
58
150
2023
9
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-0.01
-0.01
-0.01
- -
-0.04
2022
- -
0.06
0.04
- -
0.14
2023
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Qingbao Wang
Full Time Employees
27
Sector
Consumer Defensive
Industry
Packaged Foods
Address
527 Siltstone Place Cary NC United States of America 27519
IPO Date
May 28, 2014
Business
Tengjun Biotechnology Corp. Tengjun Biotechnology Corp. (TJBH), formerly China Herb Group Holdings Corp., operates as a holding company primarily engaged in the production, packaging, distribution, and marketing of featured dandelion teas and household water purifiers in the People's Republic of China. The company offers core products including Mincheng Black Dandelion Tea and Mincheng Green Dandelion Tea in various packages and sizes, emphasizing health benefits, aesthetic presentation, and cost performance through an integrated production process from dandelion cultivation and harvesting on its own farms and local arrangements to processing, packaging, and storage at facilities such as Tengjunxiang Campus I, a 52.5-acre site with a 16,000 square meter tea factory in Jining City Food Industry Park; its water purifier segment, managed through subsidiary Kanglong, designs and develops energy-conserving, environmentally friendly consumer water purifiers manufactured by partners, providing home solutions for drinking, cooking, washing, and sewer water filtration, with sales concentrated in Shandong Province and other regions. Tengjun Biotechnology Corp. conducts operations exclusively in the domestic Chinese market, targeting consumers seeking premium, health-oriented tea and water purification products, with two operating campuses and one under construction, supported by 27 employees and a research and development center focused on enhancing dandelion health benefits and production efficiency via modern tea production lines. Founded in 2010 and headquartered at East Jinze Road and South Huimin Road, Food Industry Economic and Technology Development District, Jinxiang County, Jining City, Shandong Province, China, the company completed a significant business combination on December 23, 2021, through a Share Purchase/Exchange Agreement acquiring Tengjunxiang Biotechnology Ltd., a Cayman Islands corporation, from its shareholders, marking its shift to dandelion-focused operations that began in 2017; it changed its name to Tengjun Biotechnology Corp. on December 9, 2019. Recent major changes include executive transitions, with Ruiming Zhou resigning as CEO, CFO, and Board member effective November 16, 2023, followed by appointments of Qing Bao Wang as CEO and Board member on November 15, 2023, Caihong Qu as CEO on August 9, 2023, and earlier CFO changes in September 2023, alongside a reported 52% stake acquisition in Beijing All Union Technology Corp. and a strategic focus on evaluating new industry, geographic, and market opportunities amid limited recent operational expansions or partnerships disclosed publicly as of late 2025.

Company News

APIChat
  • INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Tengjun Biotechnology Corp. and Encourages Investors with Losses to Contact the Firm

  • INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Tengjun Biotechnology Corp. and Encourages Investors with Losses to Contact the Firm

  • INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Tengjun Biotechnology Corp. and Encourages Investors with Losses to Contact the Firm

  • INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Tengjun Biotechnology Corp. and Encourages Investors with Losses to Contact the Firm

  • SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tengjun Biotechnology Corp. - TJBH

  • INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Tengjun Biotechnology Corp. and Encourages Investors with Losses to Contact the Firm

  • INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Tengjun Biotechnology Corp. and Encourages Investors with Losses to Contact the Firm

  • INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Tengjun Biotechnology Corp. and Encourages Investors with Losses to Contact the Firm

  • SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tengjun Biotechnology Corp. - TJBH

  • INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Tengjun Biotechnology Corp. and Encourages Investors with Losses to Contact the Firm

  • SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Tengjun Biotechnology Corp. and Encourages Investors with Losses to Contact the Firm

  • INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Tengjun Biotechnology Corp. and Encourages Investors with Losses to Contact the Firm

  • SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Tengjun Biotechnology Corp. and Encourages Investors with Losses to Contact the Firm

  • INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Tengjun Biotechnology Corp. and Encourages Investors with Losses to Contact the Firm

  • IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Tengjun Biotechnology Corp. and Encourages Investors with Losses to Contact the Firm

  • SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Tengjun Biotechnology Corp. and Encourages Investors with Losses to Contact the Firm

  • TENGJUN ALERT: Bragar Eagel & Squire, P.C. is Investigating Tengjun Biotechnology Corp. on Behalf of Tengjun Stockholders and Encourages Investors to Contact the Firm

  • Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Tengjun Biotechnology Corp. (TJBH) on Behalf of Investors

  • INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Tengjun Biotechnology Corp. (TJBH) on Behalf of Investors

  • The Law Offices of Frank R. Cruz Announces Investigation of Tengjun Biotechnology Corp. (TJBH) on Behalf of Investors